A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

Table 1 Patient population

	Patients
Characteristics	number	percentage
All patients	16
Sex
Male	16	50%
Female	16	50%
Age, years
Median		58
Range		36–78
Tumor site
Colon	21	65%
Rectum	11	35%
Previous adjuvant chemotherapy
Yes	10	31%
No	22	69%
Line of cetuximab use
Median		3
Range		1–5
Response status
CR	0
PR	9	28.1%
SD	12	37.5%
PD	11	34.4%

CR = Complete response, PR = Partial response, SD = Stable disease and PD = Progressive disease were defined as described in the methods section.

ISSN: 1471-2407